In the first experiment of its kind, researchers at the University of California, USA, are using natural killer cells derived from the iPS stem cells in patients with advanced solid tumors that can not be cured by known methods.
The multi-capacity stem cells (iPS) were human-developed cells in 2006 by activating 4 mutant genes in skin cells, transforming their properties completely into stem cells similar to embryonic stem cells.
Since then, multicellular stem cells have been an excellent substitute for embryonic stem cells. They have a similar ability to switch to any type of cell, and large numbers can be produced at less cost and effort than using stem cells from the patient itself or from a donor. Which has been a stumbling block in the development of clinical research involving stem cells.
The current clinical trial began in February of this year and includes 64 patients with advanced, non-treatable cancers. The aim of this trial is to test the safety of treatment, determine the response of the tumor to treatment of natural killer cells, and how much these cells can remain in the bodies of patients.
The researchers see the experience as a milestone and achievement in stem cell therapy and immunotherapy for cancer, the first clinical trial using multi-capacity stem cells developed by humans to better treat and fight cancer.
Researchers hope the results of the experiment will show by 2022, and will pave the way for a new generation of cancer treatments.
Source: Medical News Today